The rationale for using ifosfamide and cisplatin chemotherapy includes: (1) the heterologous components of the tumor may be responsive to sarcoma chemotherapy regimens (19, 20), and (2) animal model studies have indicated that cisplatin can inhibit the growth of tumors with MDM2 overexpression (21). This evidence concerns the gene MDM2 and sarcoma.